Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.00)
# 584
Out of 4,670 analysts
256
Total ratings
45.24%
Success rate
13.18%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | $4 | $0.33 | +1,130.77% | 9 | Nov 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $34.07 | +70.24% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $28.78 | +49.41% | 5 | Oct 25, 2024 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $45.59 | - | 16 | Oct 23, 2024 | |
| CYTK Cytokinetics | Reiterates: Overweight | n/a | $49.10 | - | 7 | Oct 18, 2024 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $14.60 | - | 15 | Sep 30, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $130 | $85.69 | +51.71% | 21 | Sep 20, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $107 | $98.68 | +8.43% | 20 | Sep 20, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $155 | $125.65 | +23.36% | 9 | Sep 16, 2024 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $10.15 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.41 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 | $126.67 | +10.52% | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $24.69 | +41.76% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $28 | $16.37 | +71.04% | 20 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.09 | +155.40% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.82 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.43 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.56 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.61 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.43 | - | 6 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.48 | +58.29% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $56.06 | -10.81% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.41 | -7.58% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.60 | +566.67% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.00 | +300.40% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $41.15 | +40.95% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $4.31 | +132.02% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $3.05 | +3,506.56% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $4.17 | +1,818.47% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.62 | +85.19% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.11 | +20.75% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $5.32 | +125.56% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.47 | +1,883.47% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.34 | +754.70% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $14.18 | +1,310.44% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $0.29 | +17,557.05% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.05 | +280.95% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $26.48 | -9.37% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $4.07 | +3,438.08% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $4.07 | -1.72% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 → $40 | $0.31 | +13,010.46% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $49.00 | -20.41% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $57.54 | -73.93% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $1.88 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $8.68 | +1,973.73% | 1 | Oct 9, 2017 |
Marinus Pharmaceuticals
Nov 14, 2024
Reiterates: Overweight
Price Target: $4
Current: $0.33
Upside: +1,130.77%
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $34.07
Upside: +70.24%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $28.78
Upside: +49.41%
Biohaven
Oct 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $45.59
Upside: -
Cytokinetics
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $49.10
Upside: -
Prothena Corporation
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.60
Upside: -
Intra-Cellular Therapies
Sep 20, 2024
Reiterates: Overweight
Price Target: $130
Current: $85.69
Upside: +51.71%
Axsome Therapeutics
Sep 20, 2024
Reiterates: Overweight
Price Target: $107
Current: $98.68
Upside: +8.43%
Neurocrine Biosciences
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $125.65
Upside: +23.36%
KalVista Pharmaceuticals
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.15
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $140
Current: $126.67
Upside: +10.52%
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $24.69
Upside: +41.76%
Aug 7, 2024
Maintains: Overweight
Price Target: $37 → $28
Current: $16.37
Upside: +71.04%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.09
Upside: +155.40%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.82
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.56
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.61
Upside: -
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.43
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.48
Upside: +58.29%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $56.06
Upside: -10.81%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.41
Upside: -7.58%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.60
Upside: +566.67%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.00
Upside: +300.40%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $41.15
Upside: +40.95%
Aug 22, 2023
Reiterates: Overweight
Price Target: $10
Current: $4.31
Upside: +132.02%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $3.05
Upside: +3,506.56%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.17
Upside: +1,818.47%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.62
Upside: +85.19%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.11
Upside: +20.75%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $5.32
Upside: +125.56%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.47
Upside: +1,883.47%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.34
Upside: +754.70%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $14.18
Upside: +1,310.44%
Jan 10, 2022
Initiates: Overweight
Price Target: $52
Current: $0.29
Upside: +17,557.05%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.05
Upside: +280.95%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $26.48
Upside: -9.37%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $4.07
Upside: +3,438.08%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $4.07
Upside: -1.72%
May 19, 2020
Reiterates: Overweight
Price Target: $34 → $40
Current: $0.31
Upside: +13,010.46%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $49.00
Upside: -20.41%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $57.54
Upside: -73.93%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $1.88
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $8.68
Upside: +1,973.73%